Study guide
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents
Key Takeaways Explain This Topic AI
Rapid Sequence Intubation (RSI) is the virtually simultaneous administration of a potent induction agent and a rapidly acting neuromuscular blocking agent (NMBA) to facilitate emergent endotracheal intubation while minimizing pulmonary aspiration risk without intermediate bag-valve-mask ventilation.
The operational timeline follows the 'Seven Ps of RSI': Preparation (T-10 min), Preoxygenation (T-5 min), Pretreatment (T-3 min), Paralysis with Induction (Time Zero), Positioning & Protection (T+20-30 sec), Placement with Proof (T+45-60 sec), and Post-Intubation Management (T+1-2 min).
Pretreatment agents (LOAD mnemonic: Lidocaine, Opioid [Fentanyl], Atropine, Defasciculating NMBA) are administered strictly 3 minutes prior to induction to reach peak effect-site concentration and blunt reflex sympathetic, intracranial, or bronchospastic surges.
Fentanyl (3 mcg/kg IV infused over 30-60 seconds) is the most evidence-supported pretreatment agent for blunting the reflex sympathetic response to laryngoscopy (RSRL) in acute neurovascular emergencies (aSAH, ICH, TBI) and acute aortic dissection; rapid push risks chest wall rigidity.
Routine atropine premedication is not recommended for pediatric intubation; when bradycardia risk is high (young infants, repeat succinylcholine) the AHA PALS guidance allows 0.02 mg/kg with no minimum dose for this indication, and defasciculating NMBA doses are obsolete.
Last updated: October 2026
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around official Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination specifications.
Clinical Indications & Resuscitative Objectives
Rapid Sequence Intubation (RSI) is the cornerstone airway management strategy in emergency medicine and critical care resuscitation. It is defined as the virtually simultaneous administration of a potent sedative-hypnotic induction agent and a rapidly acting neuromuscular blocking agent (NMBA) to induce immediate unconsciousness and flaccid motor paralysis. The primary clinical objective is to achieve optimal conditions for endotracheal intubation within 45 to 60 seconds while minimizing gastric insufflation, regurgitation and aspiration in an unfasted emergency patient. Classic RSI avoided bag-mask ventilation during apnea, but the PreVent trial (2019) showed that gentle bag-mask ventilation between induction and laryngoscopy reduced severe hypoxemia without increasing aspiration, so many clinicians now ventilate patients at risk of desaturation.
Emergency airway intervention is indicated across three distinct clinical scenarios:
Failure of Airway Maintenance or Protection : Loss of protective pharyngeal reflexes, depressed consciousness (Glasgow Coma Scale [GCS] ≤8), massive upper gastrointestinal hemorrhage, severe maxillofacial trauma, or active pooling of secretions.
Failure of Oxygenation or Ventilation : Severe hypoxemic respiratory failure refractory to high-flow nasal cannula or noninvasive positive pressure ventilation (e.g., severe ARDS, multifocal pneumonia), or severe acute hypercapnic respiratory acidosis with respiratory muscle exhaustion.
Anticipated Clinical Deterioration : Clinical trajectories pointing toward imminent airway loss, including progressive angioedema, expanding neck hematomas, thermal inhalation burns with stridor, severe sepsis requiring invasive ventilation to decrease the work of breathing, or polytrauma requiring immediate operative intervention.
Physiological Hazards of Airway Instrumentation
Laryngoscopy and passage of an endotracheal tube (ETT) are intensely noxious mechanical stimuli. Forceful instrumentation of the base of the tongue, epiglottis, and vocal cords stimulates rich somatic and visceral afferents carried by the glossopharyngeal (cranial nerve IX) and vagus (cranial nerve X) nerves. In an inadequately blunted patient, this sensory input activates the vasomotor centers of the brainstem, triggering the Reflex Sympathetic Response to Laryngoscopy (RSRL) .
The RSRL causes a massive surge in endogenous catecholamines (norepinephrine and epinephrine), resulting in acute hypertension, tachycardia, and increased systemic vascular resistance. In vulnerable patient populations, these acute hemodynamic perturbations can have catastrophic consequences:
Acute Neurovascular Emergencies : In aneurysmal subarachnoid hemorrhage (aSAH), acute intracerebral hemorrhage (ICH), or severe traumatic brain injury (TBI), an abrupt spike in mean arterial pressure (MAP) elevates intracranial pressure (ICP) and increases transmural aneurysm stress, precipitating fatal aneurysm re-rupture, hematoma expansion, or brainstem herniation.
Cardiovascular Crises : In acute aortic dissection (Stanford Type A or B), the sudden rise in myocardial contractility and blood pressure accelerates the rate of aortic pressure change ( Δ P / Δ t \Delta P / \Delta t Δ P /Δ t ), propagating dissection tears. In acute coronary syndromes (ACS), tachycardia dramatically increases myocardial oxygen consumption ( M V O 2 MVO_2 M V O 2 ) while shortening diastolic coronary perfusion time.
Reactive Airway Disease : Direct stimulation of the tracheobronchial tree triggers parasympathetic cholinergic efferents that induce severe, life-threatening reflex bronchoconstriction in patients with acute status asthmaticus or severe chronic obstructive pulmonary disease (COPD).
The Seven Ps of RSI Operational Timeline
Emergency RSI follows an operational checklist structured around the Seven Ps , establishing a synchronized countdown from ten minutes prior to intubation through post-intubation stabilization:
Step Operational Timing Procedural Actions Pharmacotherapy & Clinical Pearls
1. Preparation Zero minus 10 min ( T − 10 T-10 T − 10 ) Assemble equipment, verify suction, evaluate airway difficulty (LEMON criteria), establish IV/IO access, attach continuous monitors. Confirm medication doses based on actual vs. ideal body weight; prepare rescue airway devices (video laryngoscope, supraglottic airway, cricothyrotomy kit).
2. Preoxygenation Zero minus 5 min ( T − 5 T-5 T − 5 ) Replace nitrogen in functional residual capacity (FRC) with 100% O 2 O_2 O 2 using NRB mask at flush rates (≥15 L/min) or NIPPV/HFNC for 3–5 minutes. Extends 'safe apnea time' (time to S a O 2 < 90 % SaO_2 <90\% S a O 2 < 90% ) from 1–2 minutes up to 8–10 minutes in healthy adults (reduced to 2–4 min in critically ill patients).
3. Pretreatment Zero minus 3 min ( T − 3 T-3 T − 3 ) Administer targeted adjunctive medications to blunt physiological surges (ICP spikes, sympathetic storm, reflex bronchospasm). Fentanyl (3 mcg/kg IV over 30–60 s) for sympathetic surge; Lidocaine (1.5 mg/kg IV) for reactive airway/ICP; Atropine (0.02 mg/kg IV) in pediatrics.
4. Paralysis with Induction Time Zero ( T − 0 T-0 T − 0 ) Administer rapid IV push of induction agent immediately followed by rapid IV push of neuromuscular blocking agent. Induction: Etomidate 0.3 mg/kg, Ketamine 1.5–2 mg/kg, or Propofol 1.5–2.5 mg/kg. Paralytic: Succinylcholine 1.5–2 mg/kg or Rocuronium 1.2 mg/kg.
5. Positioning & Protection Zero plus 20–30 s ( T + 20 s T+20\text{ s} T + 20 s ) Align airway axes into the 'sniffing position'; ramp morbidly obese patients; avoid routine cricoid pressure. Ear-to-sternal notch alignment optimizes laryngeal visualization. Sellick maneuver (cricoid pressure) is no longer recommended as it distorts glottic views.
6. Placement with Proof Zero plus 45–60 s ( T + 45 s T+45\text{ s} T + 45 s ) Perform laryngoscopy, pass cuffed ETT through vocal cords, inflate cuff, verify tube position. Continuous waveform capnography ( E t C O 2 EtCO_2 EtC O 2 ) is the mandatory gold standard for confirmation (≥4–6 consistent square waveforms). Auscultate 5 points.
7. Post-Intubation Management Zero plus 1–2 min ( T + 1 min T+1\text{ min} T + 1 min ) Secure ETT, obtain chest radiograph (tip 3–5 cm above carina), optimize ventilator settings, initiate continuous analgosedation. Initiate immediate analgesia and sedation before induction agent wears off to prevent traumatic patient awareness during prolonged paralysis.
Physiological Foundations of Preoxygenation & Apneic Oxygenation
Preoxygenation achieves 'denitrogenation' of the lungs. Ambient air is composed of approximately 78% nitrogen and 21% oxygen. During 3 to 5 minutes of tidal volume breathing at 100% F i O 2 FiO_2 F i O 2 (or 8 vital capacity breaths), alveolar nitrogen is washed out and replaced with oxygen, transforming the patient's functional residual capacity (FRC)—approximately 30 mL/kg—into an internal oxygen reservoir.
In a healthy 70-kg adult, this reservoir provides approximately 2,000 mL of oxygen, extending the safe apnea time (the duration of apnea before pulse oximetry falls below 90%) to 8 to 10 minutes . However, in critically ill emergency patients, safe apnea time is profoundly shortened (often to under 2 to 3 minutes ) due to:
Increased metabolic oxygen consumption ( V O 2 VO_2 V O 2 ) from sepsis, fever, or agitation.
Reduced FRC from obesity, supine positioning, abdominal distension, or chest wall trauma.
Significant intrapulmonary shunt (e.g., severe pneumonia, pulmonary contusion, ARDS) where non-ventilated alveoli perfuse deoxygenated blood directly into systemic circulation.
Important
In patients with severe physiological shunt who remain hypoxemic despite a non-rebreather mask, preoxygenation should be performed using Noninvasive Positive Pressure Ventilation (NIPPV) with PEEP (5–10 cmH 2 O \text{cmH}_2\text{O} cmH 2 O ) or High-Flow Nasal Cannula (HFNC) at 60 L/min. Furthermore, apneic oxygenation —maintaining standard nasal cannula oxygen at 15 L/min throughout the apneic period from induction until tube confirmation—harnesses continuous alveolar oxygen uptake to maintain oxygen saturation and significantly delays critical desaturation.
Pretreatment Pharmacotherapy: The LOAD Regimen & Evidence Base
Pretreatment medications are administered strictly 3 minutes prior to induction ( T − 3 T-3 T − 3 minutes). This 3-minute interval ensures that the agent crosses the blood-brain barrier and achieves peak effect-site receptor concentration precisely when laryngoscopy and intubation occur. The historical mnemonic LOAD categorizes the four potential pretreatment classes: PRETREATMENT PHARMACOTHERAPY (LOAD)
- ┌─────────────────────────────────────────────────────────────────────────────────┐
- │ L - Lidocaine (1.5 mg/kg IV) │ Blunts bronchospasm & cough reflex │
- ├─────────────────────────────────────────────────────────────────────────────────┤
- │ O - Opioid / Fentanyl (3 mcg/kg IV) │ Blunts reflex sympathetic response (RSRL)│
- ├─────────────────────────────────────────────────────────────────────────────────┤
- │ A - Atropine (0.02 mg/kg IV) │ Prevents vagal reflex bradycardia in peds│
- ├─────────────────────────────────────────────────────────────────────────────────┤
- │ D - Defasciculating NMBA (Obsolete) │ Historically prevented fasciculations │
- └─────────────────────────────────────────────────────────────────────────────────┘
- 1. Fentanyl (Opioid Pretreatment)
Dose & Route : 3 mcg/kg IV administered slowly over 30 to 60 seconds at T − 3 T-3 T − 3 minutes.
Pharmacodynamics : Highly lipophilic, synthetic μ \mu μ -opioid receptor agonist with an onset of 1 to 2 minutes and duration of 30 to 60 minutes. It acts centrally within the brainstem to suppress sympathetic outflow, blunting the reflex surge of epinephrine and norepinephrine triggered by laryngoscopy.
Primary Clinical Indications :
Acute intracranial pathology: Aneurysmal subarachnoid hemorrhage (aSAH), acute intracerebral hemorrhage (ICH), severe traumatic brain injury (TBI) with suspected intracranial hypertension.
Acute cardiovascular disasters: Stanford Type A or Type B aortic dissection, acute myocardial infarction, unstable angina.
Cautions & Pitfalls : Fentanyl blunts compensatory sympathetic tone. In patients with unresuscitated hypovolemic, hemorrhagic, or septic shock, a 3 mcg/kg dose can precipitate severe hypotension or circulatory collapse. Rapid IV push boluses of high-dose fentanyl can induce chest wall and glottic rigidity ('wooden chest syndrome'), severely impeding rescue bag-valve-mask ventilation.
2. Lidocaine
Dose & Route : 1.5 mg/kg IV (maximum 100 mg) administered at T − 3 T-3 T − 3 minutes.
Pharmacodynamics : Class Ib antiarrhythmic and local anesthetic that reversibly blocks voltage-gated sodium channels in airway mechanoreceptors and central cough reflex arcs. It suppresses airway sensory nerve signaling, attenuates reflex bronchoconstriction, and modestly blunts increases in ICP.
Primary Clinical Indications : Severe reactive airway disease (acute status asthmaticus, severe COPD exacerbation) undergoing emergency intubation. Historically advocated for acute traumatic brain injury; however, contemporary neurocritical guidelines regard the evidence for ICP reduction as weak and equivocal.
Contraindications : High-grade atrioventricular (AV) block, severe bradycardia, cardiogenic shock, or known hypersensitivity to amide-type local anesthetics.
3. Atropine
Dose & Route : 0.02 mg/kg IV ; maximum single dose 0.5 mg IV in children (1 mg in adolescents and adults). When atropine is used as premedication for emergency intubation , AHA PALS guidance (2015, carried forward) states that a dose of 0.02 mg/kg with no minimum dose may be considered. The traditional 0.1 mg minimum still appears in some bradycardia references.
Pharmacodynamics : Competitive antagonist at muscarinic acetylcholine receptors. It blocks vagal parasympathetic stimulation to the sinoatrial (SA) and atrioventricular (AV) nodes.
Primary Clinical Indications :
Pediatric intubation in infants < 1 <1 < 1 year of age receiving succinylcholine (infants possess high baseline vagal tone and immature sympathetic innervation, making them exquisitely prone to profound reflex bradycardia during laryngoscopy).
Children < 5 <5 < 5 years receiving a second dose of succinylcholine.
Patients experiencing symptomatic bradycardia during airway manipulation.
The Paradoxical Bradycardia Debate : Very small atropine doses were long thought to cause paradoxical bradycardia by blocking presynaptic M 1 M_1 M 1 autoreceptors, which is why a 0.1 mg minimum was taught. Pediatric data did not support a minimum dose for intubation premedication, and AHA PALS guidance dropped it for that use. Routine atropine premedication for every pediatric intubation is not recommended; reserve it for children at higher risk of bradycardia, such as young infants and those receiving a second dose of succinylcholine.
4. Defasciculating Non-Depolarizing NMBAs (Historical Practice)
Regimen : 10% of a standard intubating dose of a non-depolarizing NMBA (e.g., Rocuronium 0.06 mg/kg IV or Vecuronium 0.01 mg/kg IV) administered 3 minutes prior to succinylcholine.
Historical Rationale : Theorized to occupy motor endplate receptors, preventing the visible muscle fasciculations caused by succinylcholine, which were believed to cause postoperative myalgias and spike ICP, intraocular pressure (IOP), and intragastric pressure.
Contemporary Evidence : Defasciculation has been largely abandoned in modern emergency medicine . Rigorous clinical trials demonstrate that succinylcholine-induced fasciculations do not produce clinically meaningful elevations in ICP or adverse neurological outcomes. Furthermore, administering a defasciculating dose causes distressing partial paralysis, diplopia, and severe dyspnea in an awake, anxious patient. If succinylcholine fasciculations or hyperkalemia are a clinical concern, the contemporary evidence-based solution is to utilize high-dose rocuronium (1.2 mg/kg IV) rather than complex defasciculating regimens.
Pretreatment Agent Comparative Matrix
Agent Dose & Route Onset / Timing Mechanism of Action Clinical Indication Key Contraindications & Hazards
Fentanyl 3 mcg/kg IV over 30–60 s Peak 2–3 min (Give at T − 3 T-3 T − 3 ) μ \mu μ -opioid receptor agonist; blunts central sympathetic outflow (RSRL) Intracranial hemorrhage, aSAH, acute aortic dissection, ACS Decompensated shock, hypotension; rapid push risks chest wall rigidity
Lidocaine 1.5 mg/kg IV Peak 2–3 min (Give at T − 3 T-3 T − 3 ) Fast sodium channel blockade; blunts airway reflexes and cough arcs Acute status asthmaticus, reactive airway disease High-grade heart block, severe bradycardia, local anesthetic allergy
Atropine 0.02 mg/kg IV (no minimum for intubation premedication) Peak 1–2 min (Give at T − 3 T-3 T − 3 ) Muscarinic acetylcholine receptor antagonist; blocks vagal bradycardia Infants < 1 <1 < 1 yr receiving succinylcholine; repeat succinylcholine Not routine; tachyarrhythmias; older teaching cited a 0.1 mg minimum
Rocuronium (Defasciculating) 0.06 mg/kg IV (10% intubating dose) Peak 2–3 min (Give at T − 3 T-3 T − 3 ) Competitive non-depolarizing nAChR blockade Obsolete; historical prevention of succinylcholine fasciculations Awake weakness, dyspnea, sensation of suffocation; largely abandoned
- Worked Clinical Case & Practice Pearls
- Clinical Vignette
A 54-year-old female (actual weight 70 kg, height 5'6") presents to the emergency department with a sudden-onset, catastrophic 'thunderclap' headache, vomiting, and rapidly declining mental status. On examination, she is moaning incomprehensibly with non-purposeful withdrawal to painful stimuli (GCS 7). Vital signs: blood pressure 218/118 mmHg, heart rate 108 bpm, respiratory rate 12 breaths/min, and S p O 2 SpO_2 Sp O 2 93% on room air. Non-contrast cranial CT reveals diffuse subarachnoid hemorrhage with intraventricular extension (Hunt-Hess Grade 3, modified Fisher Grade 4) secondary to a suspected ruptured anterior communicating artery aneurysm. The emergency team prepares for immediate RSI to secure the airway.
Pharmacotherapeutic Care Plan
Preoxygenation ( T − 5 T-5 T − 5 to T − 0 T-0 T − 0 ) : Apply 100% F i O 2 FiO_2 F i O 2 via non-rebreather mask at flush rate ( > 15 >15 > 15 L/min) combined with continuous nasal cannula at 15 L/min for apneic oxygenation.
Pretreatment Selection & Dosing ( T − 3 T-3 T − 3 ) :
Target Physiological Goal : Completely blunt the RSRL to prevent an acute blood pressure surge that would increase transmural aneurysm pressure and trigger catastrophic rebleeding.
Drug & Calculation : Fentanyl 3 mcg/kg IV × \times × 70 kg = 210 mcg IV .
Administration Technique : Administer 200 mcg IV push slowly over 60 seconds exactly 3 minutes prior to induction.
Induction & Paralysis ( T − 0 T-0 T − 0 ) : Etomidate 0.3 mg/kg IV (20 mg) plus Rocuronium 1.2 mg/kg IV (84 mg, rounded to 90 mg).
Outcome : Laryngoscopy is performed smoothly at T + 50 T+50 T + 50 seconds; the patient's blood pressure remains stable at 145/85 mmHg throughout instrumentation without reflex tachycardia or hypertensive spiking.
Warning
Never administer fentanyl pretreatment as a rapid IV push. Administering 3 mcg/kg over 2 to 3 seconds can trigger acute glottic closure and wooden chest syndrome, rendering bag-mask ventilation and rescue supraglottic airway placement impossible. Always infuse the pretreatment dose steadily over 30 to 60 seconds.